(no title)
LeifCarrotson | 21 days ago
Modern society basically decided that adding flouride to drinking water and iodine to table salt for everyone was better than dealing with tooth decay and gout.
I understand that peptide synthesis and cold-chain logistics are not as trivial as these elements, but this paper [1] estimates that GLP1 manufacturing costs can be under a dollar per person per month, orders of magnitude less than current market rates!
Perhaps our future society will normalize taking a daily GLP-1 agonist with their other multivitamins at breakfast.
[1]: https://jamanetwork.com/journals/jamanetworkopen/fullarticle...
sReinwald|21 days ago
If health insurance companies would be able to cover these drugs, there'd have to be negotiations between Eli Lilly and the insurance companies, and insurance companies have a bigger lever than individual patients who pay out of pocket. Self-payers are just price-takers. We pay whatever Eli Lilly wants us to pay.
nerdsniper|20 days ago
Another way to check if the marginal cost of production contributes to the cost of the drug is to compare the price of injectable semaglutide (~$1200) for around 10mg/month, to the price of oral semaglutide (Rybelsus), which is also (~$1,000) for around 420mg/month. That indicates that the cost of manufacturing semaglutide does not significantly contribute to the cost of the FDA-approved drug.
MattGaiser|21 days ago
thisisit|21 days ago